Factor Bioscience to Unveil iMacrophages Engineered to Combat Solid Tumors at the ISSCR Annual Meeting

-Presentations will include the latest preclinical data from Factor's engineered iMacrophage program (FACT-112)

-Factor to reveal latest advances in RNA-based gene editing and directed differentiation platforms

CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced its participation in the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting to be held in Hong Kong from June 11-14, 2025. Factor will deliver three presentations covering the latest preclinical data from FACT-112, Factor's engineered iMacrophage program, as well as recent advances in Factor's gene editing and cell differentiation platforms.

"We are excited to present the latest data from our engineered iMacrophage program, as well as recent advances in our gene editing and cell differentiation platforms at ISSCR 2025," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "The data we will be showcasing this week include the first demonstration of targeted delivery of IL-12, a potent immunomodulatory cytokine with established anti-tumor activity, to the solid tumor microenvironment using engineered macrophages. These results represent a major milestone in our work to develop new therapies to treat cancer."

Dr. Kyle Garland, Factor's Director of Translational Science, added, "After spending more than a decade laying the groundwork by developing cutting-edge RNA-based cell-engineering technologies, Factor is now leveraging these innovative platforms to develop next-generation therapies for patients in need. We are excited to share these remarkable advances in Hong Kong over the next few days."

Details of the presentations are below:

1. "Hypoimmune iPSC-derived Macrophages Engineered to Express IL-12 Activate Lymphocytes Against Platinum-Resistant Ovarian Cancer." -to be presented by Ian Hay on June 13 from 4:00-5:00 pm HKST, Organ Generation and Regeneration (OGR) and Clinical Applications (CA) Session 3: (Poster Presentation #F1249), Exhibit & Poster Hall (3BCDE, Level 3).
   
   
2. "UltraSlice™ mRNA Incorporating 5-Methoxyuridine Efficiently Inserts Transgene Sequences in iPSCs with High Viability and Mitigates dsRNA Production." -to be presented by Cassandra Ng on June 12 from 5:00-6:00 pm HKST, Disease Modeling and Drug Discovery (DMDD) Continued, Pluripotency and Development (PD) Session 2: (Poster Presentation #T1348), Exhibit & Poster Hall (3BCDE, Level 3).
   
   
3. "Directed Differentiation of mRNA-Reprogrammed iPSCs via Bioreactors Generates Clinically Relevant Yields of Neural Stem and Progenitor Cells that can be Engineered to Secrete Therapeutic Proteins." -to be presented by Claire Aibel on June 13 from 5:00-6:00 pm HKST, Organ Generation and Regeneration (OGR) and Clinical Applications (CA) Session 3: (Poster Presentation #F1228), Exhibit & Poster Hall (3BCDE, Level 3).

For more information about the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, visit http://www.isscr2025.org/.

About FACT-112
FACT-112 is an mRNA-reprogrammed macrophage engineered using Factor's patented UltraSlice™ gene editing platform to deliver IL-12 to solid tumors. Factor is developing FACT-112 for the treatment of platinum-resistant ovarian cancer and other malignant neoplasms.

About Factor Bioscience
Founded in 2011, Factor Bioscience is a biotechnology company focused on using its patented gene-editing platform to develop life-saving cell and gene therapies. Factor Bioscience is privately held and headquartered in Cambridge, MA. For more information, visit www.factorbio.com.

SOURCE Factor Bioscience Inc.